Skip to main content
Premium Trial:

Request an Annual Quote

FDA Clears Prodesse's Human Metapneumovirus Assay

NEW YORK (GenomeWeb News) – Prodesse today said that it has received US Food and Drug Administration clearance to market its ProhMPV+ Assay for detecting human metapneumovirus just two months after filing its submission for the test.
 
According to the Milwaukee-based firm, the assay is the first real-time molecular diagnostic test for HMPV to receive FDA clearance. It also is the second of Prodesse’s family of respiratory virus assays to gain FDA clearance. The firm received FDA clearance for its ProFlu Assay last January.
 
Prodesse said that the assay is sold with all royalties fully paid, so labs running the test would not have to make any additional payments to patent holders.
 
“With new ASR guidelines being enforced by the FDA as of September 2008, it has become critically important for manufacturers to gain clearance for their products,” Prodesse CEO Tom Shannon said in a statement.
 
Prodesse is currently conducting clinical trials on its real-time assay for parainfluenza viruses, and is developing another assay for adenovirus.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.